For years, people have been asking: "Which GLP-1 drug is better for weight loss. tirzepatide or semaglutide?"
We finally have an answer. The SURMOUNT-5 trial put them head-to-head in 751 people for 72 weeks. Tirzepatide won, and it wasn't close.
The numbers that matter
After 72 weeks:
- Tirzepatide group: 20.2% average body weight loss
- Semaglutide group: 13.7% average body weight loss
That's 47% more weight loss with tirzepatide.
To put that in perspective: if you weigh 100kg (220 lbs), tirzepatide would get you down to about 80kg on average, while semaglutide would get you to 86kg.
Both are impressive. But the gap is real.
How the trial actually worked
SURMOUNT-5 randomized 751 adults with obesity or overweight (but no type 2 diabetes) into two groups:
Group 1: Tirzepatide 10-15mg weekly (maximum tolerated dose) Group 2: Semaglutide 1.7-2.4mg weekly (maximum tolerated dose)
Everyone got weekly injections for 72 weeks. Researchers measured body weight change as the primary endpoint.
Important: these weren't healthy 25-year-olds trying to lose 5kg. Participants had real comorbidities. hypertension, sleep apnea, and other weight-related conditions.
Who hit the big milestones?
The trial also tracked how many people achieved major weight loss thresholds:
≥25% body weight loss:
- Tirzepatide: 31.6% of participants
- Semaglutide: 16.1% of participants
That's nearly double. Almost one in three people on tirzepatide lost a quarter of their starting weight. On semaglutide, it was one in six.
≥15% body weight loss:
- Tirzepatide: ~75% of participants (estimated from prior trials)
- Semaglutide: ~55% of participants (estimated from prior trials)
Again, tirzepatide pulls ahead.
Why does tirzepatide work better?
Semaglutide is a GLP-1 agonist. It mimics one gut hormone (GLP-1) that tells your brain you're full and slows stomach emptying.
Tirzepatide is a dual GLP-1/GIP agonist. It mimics two gut hormones. GLP-1 and GIP. The addition of GIP seems to amplify weight loss, though scientists are still figuring out exactly how.
The leading theory: GIP improves insulin sensitivity and may affect how your body stores fat. Combined with GLP-1's appetite suppression, you get a stronger effect.
What about side effects?
Both drugs cause gastrointestinal side effects. That's just how GLP-1 drugs work. they slow your digestion.
In SURMOUNT-5:
- Nausea, vomiting, diarrhea were the most common complaints
- Side effects were mild to moderate in most cases
- Dropout rates were similar between both groups
Neither drug was significantly worse in terms of tolerability. If you can handle one, you can probably handle the other.
Real-world data: tirzepatide may reduce dementia risk
A separate study published in January 2026 looked at 12,246 people with type 2 diabetes taking tirzepatide vs. semaglutide.
The finding: tirzepatide users had a 31% lower risk of developing dementia over 2 years compared to semaglutide users (hazard ratio 0.69, 95% CI 0.48-0.99).
This wasn't a randomized trial. it was a retrospective analysis using real-world medical records. So take it with appropriate caution. But it's hypothesis-generating.
Why would tirzepatide reduce dementia risk more than semaglutide? Possibly because GIP receptors exist in the brain and may play a role in neuroinflammation and cognitive function. We don't know yet. More research is needed.
So which one should you take?
Choose tirzepatide if:
- You want maximum weight loss
- You can access it (availability varies by country)
- Cost isn't a barrier (tirzepatide is often more expensive)
Choose semaglutide if:
- Tirzepatide isn't available or affordable
- You're already seeing good results on semaglutide (no need to switch if it's working)
- Your doctor recommends it based on your specific health situation
Skip both if:
- You're not willing to commit to long-term injections
- You can't tolerate GI side effects
- You haven't tried lifestyle changes first (these drugs work best as tools, not magic bullets)
The bigger picture
SURMOUNT-5 proves what many doctors suspected: tirzepatide is the most effective weight loss drug we have right now.
But "most effective" doesn't mean "only option." Semaglutide still delivers 13.7% average weight loss, which is better than almost any other intervention short of bariatric surgery.
And we're still early. Oral versions, triple agonists, and other next-gen drugs are in development. The GLP-1 class is evolving fast.
For now, if you're choosing between tirzepatide and semaglutide, the data is clear: tirzepatide wins on weight loss. Whether it's worth the extra cost or effort to access depends on your specific situation.
Key takeaways
- Tirzepatide beat semaglutide in the first head-to-head trial: 20.2% vs. 13.7% weight loss after 72 weeks
- 31.6% of tirzepatide users lost ≥25% of their body weight (vs. 16.1% on semaglutide)
- Side effects were similar. mostly mild-to-moderate GI issues
- Real-world data hints at possible cognitive benefits for tirzepatide, but more research is needed
- Both drugs are effective. tirzepatide is just more effective
---
This is educational content, not medical advice. Talk to your doctor before starting any GLP-1 protocol.